EP0252290A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof
Assignee: Chiesi Farmaceutici SpA
•
Filing: 1987-06-02
•
Granted: —
•
Expires: 2007-06-02
Abstract
Abstract Pharmaceutical compositions for the treatment of Parkinson's disease and neurologic syndromes connected with it, containing as the active principle levodopa methyl ester optionally combined with other active principles selected from dopaminergic, anticholinergic, antidepressive drugs, carboxylase and monoaminoxidase inhibitors.
Inventors
- 👤 Paolo Chiesi
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-28 22:45
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61K31/195; A61K31/21; A61K31/215; A61K31/235; A61K31/24; A61P; A61P25/00
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
16 words
Pharmaceutical compositions containing levodopa methyl ester (LDME) as active ingredient and a pharmaceutical carrier or diluent.
Claim 2
Dependent Claim
16 words
Pharmaceutical compositions containing levodopa methyl ester (LDME) as active ingredient and a pharmaceutical carrier or diluent.
Claim 3
Dependent Claim
27 words
Compositions according to claim 1, containing LDME in combination with other active principles selected from dopamine agonists, anticholinergics, antidepressives, peripheral decarboxylase inhibitors, MAO-B inhibitors or their association.
Claim 4
Dependent Claim
24 words
Compositions according to claims 1 and 2 containing as active ingredient LDME alone or in combination, in solution in a liquid carrier or diluent.
Claim 5
Dependent Claim
25 words
Compositions according to claims 1 and 2 containing as active ingredient LDME alone or in combination, in solid form in a solid carrier or diluent.
Claim 6
Dependent Claim
24 words
Compositions according to claims 1 to 4 to be administered by oral, buccal, sublingual, rectal, parenteral, subantaneous or endoperitoneal route, optionally through implantable systems.
Claim 7
Dependent Claim
41 words
Compositions according to any one of the preceding claims containing from 100 to 1.000 mg of active ingredient per unit dose, when in solid form, or containing the active principle in concentration from 50 to 400 mg/ml, when in liquid form.
Claim 8
Dependent Claim
46 words
Compositions according to claims 2 and 4 containing levodopa methyl ester in an unit dose ranging from 100 to 300 mg in combination with benserazide or carbidopa or deprenyl, in a ratio from respectively 2:1 to 5:1; 4:1 to 10:1; 20:1 to 100:1 or their combination.
Claim 9
Dependent Claim
45 words
Compositions according to claims 2 and 3 containing levodopa methyl ester in a concentration ranging from 50 to 400 mg/ml in combination with benserazide or carbidopa or deprenyl in a ratio between respectively 2:1 and 10:1; 4:1 and 20:1; 20:1 to 100:1 or their combination.
Claim 10
Dependent Claim
25 words
Compositions according to any one of the preceding claims characterized in that the release of the active ingredient occurs in a prolonged or sequential way.
Claim 11
Dependent Claim
19 words
Compositions according to any one of the preceding claims to be administered so as to bypass the gastrointestinal system.
Claim 12
Dependent Claim
20 words
Use of LDME for the preparation of a medicament useful in the treatment of Parkinson's disease and correlated neurologic syndrome.
Claim 13
Dependent Claim
20 words
Use of LDME for the preparation of a medicament useful in the treatment of Parkinson's disease and correlated neurologic syndrome.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.